About CytomX Therapeutics, Inc. - Common Stock (CTMX)
CytomX Therapeutics is a biotechnology company focused on developing innovative cancer therapies through its proprietary Probody™ therapeutic technology. This platform is designed to selectively activate antibody-based treatments in the tumor microenvironment, helping to enhance the efficacy and reduce potential side effects of cancer therapies. CytomX is engaged in creating a pipeline of product candidates aiming to address various types of cancer, leveraging its expertise in protein engineering and immuno-oncology to advance treatment options and improve patient outcomes. The company collaborates with pharmaceutical partners to accelerate the development of its therapeutic candidates, with the goal of bringing novel, targeted therapies to market. Read More
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million.
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
CytomX Therapeutics (CTMX) Q2 2025 revenue beat estimates at $18.66M, with break-even EPS. Shares rose slightly as clinical progress, including CX-2051 data, boosts optimism.
